Retinal Thickening and Photoreceptor Loss in HIV Eyes without Retinitis.

Autor: Cheryl A Arcinue, Dirk-Uwe Bartsch, Sharif Y El-Emam, Feiyan Ma, Aubrey Doede, Lucie Sharpsten, Maria Laura Gomez, William R Freeman

Publikováno v: PLoS ONE, Vol 10, Iss 8, p e0132996 (2015)

PURPOSE:To determine the presence of structural changes in HIV retinae (i.e., photoreceptor density and retinal thickness in the macula) compared with age-matched HIV-negative controls. METHODS:Cohort of patients with known HIV under CART (combinatio

Externí odkaz: https://doaj.org/article/10f616d02e834c908e5cc8bd66d36472

SALT Trial: Steroids after Laser Trabeculoplasty

Autor: Roman G. Fajardo, Jeffrey L. Goldberg, Lucie Sharpsten, Joel S. Schuman, Mariana Nunez, Nils A. Loewen, Sylvia L. Groth, Eiyass Albeiruti

Publikováno v: Ophthalmology. 126:1511-1516

Purpose This study examined whether short-term use of topical nonsteroidal anti-inflammatory drug (NSAID) or steroid therapy affected the efficacy of selective laser trabeculoplasty (SLT). Design Double-masked, randomized, placebo-controlled, dual-ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56507cbe8f8b7bce408064ad778cb2a1
https://doi.org/10.1016/j.ophtha.2019.05.032

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Autor: Alexandra Arias-Mendoza, Felix J. A. Ramires, Karen Sliwa, Tor Biering-Sørensen, Vyacheslav Mareev, Pranas Šerpytis, Rafael Diaz, Jonathan G. Howlett, Assen Goudev, Eileen O'Meara, Cândida Fonseca, Christopher E. Kurtz, Scott D. Solomon, Kirkwood F. Adams, Eva Goncalvesova, Luis E. Echeverría Correa, Diana Bonderman, John R. Teerlink, Michael Böhm, M. Lund, Galactic-Hf Investigators, Fady I. Malik, Jason C. Legg, María G. Crespo-Leiro, Ulf Dahlström, Lucie Sharpsten, Alexander Parkhomenko, Piotr Ponikowski, Peter S. Macdonald, James C. Fang, Ramón Corbalán, Thomas M. Suter, Mehmet Yilmaz, Gerasimos Filippatos, Jindrich Spinar, Hans Vandekerckhove, Shin-ichi Momomura, Faiez Zannad, János Tomcsányi, Adriaan A. Voors, G. Michael Felker, Inder S. Anand, John J.V. McMurray, Siddique Abbasi, Dragos Vinereanu, David E Lanfear, Claire Varin, John G.F. Cleland, Marco Metra

Publikováno v: European Journal of Heart Failure, 22(11), 2160-2171. Wiley
Teerlink, J R, Diaz, R, Felker, G M, McMurray, J J V, Metra, M, Solomon, S D, Adams, K F, Anand, I, Arias-Mendoza, A, Biering-Sorensen, T, Bohm, M, Bonderman, D, Cleland, J G F, Corbalan, R, Crespo-Leiro, M G, Dahlstrom, U, Echeverria Correa, L E, Fang, J C, Filippatos, G, Fonseca, C, Goncalvesova, E, Goudev, A R, Howlett, J G, Lanfear, D E, Lund, M, Macdonald, P, Mareev, V, Momomura, S, O'Meara, E, Parkhomenko, A, Ponikowski, P, Ramires, F J A, Serpytis, P, Sliwa, K, Spinar, J, Suter, T M, Tomcsanyi, J, Vandekerckhove, H, Vinereanu, D, Voors, A A, Yilmaz, M B, Zannad, F, Sharpsten, L, Legg, J C, Abbasi, S A, Varin, C, Malik, F I, Kurtz, C E & GALACTIC HF Investigators 2020, ' Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction : GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials ', European Journal of Heart Failure, vol. 22, no. 11, pp. 2160-2171 . https://doi.org/10.1002/ejhf.2015
Eur J Heart Fail
European journal of heart failure, Hoboken : John Wiley and Sons Ltd, 2020, vol. 22, iss. 11, p. 2160-2171
European Journal of Heart Failure
European Journal of Heart Failure, 2020, 22 (11), pp.2160-2171. ⟨10.1002/ejhf.2015⟩
RUC: Repositorio da Universidade da Coruña
Universidade da Coruña (UDC)
RUC. Repositorio da Universidade da Coruña
instname

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Throug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f000e290f8ad64a47f31d4c9a07593e9
https://research.rug.nl/en/publications/1dc2cc6b-2c2d-4680-b6c8-a27ff9da2c76

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Autor: Eleena Koep, Lee Brekke, Beth Hahn, Richard H. Stanford, Riju Ray, Ami R Buikema, Lucie Sharpsten, Damon Van Voorhis, Amy Anderson

Publikováno v: Multidisciplinary Respiratory Medicine, Vol 13, Iss 1, Pp 1-9 (2018)
Multidisciplinary Respiratory Medicine

Background Chronic obstructive pulmonary disease (COPD) is associated with high clinical and economic burden. Optimal pharmacological therapy for COPD aims to reduce symptoms and the frequency and severity of exacerbations. Umeclidinium/vilanterol (U

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03cc638eafb0bdc07e8f1153c3c27605
https://doi.org/10.4081/mrm.2018.194

ECONOMIC IMPACT OF EARLY USE OF UMEC/VI COMPARED WITH LATER USE IN PATIENTS WITH COPD

Autor: Ami R Buikema, Damon Van Voorhis, Lucie Sharpsten, Beth Hahn, Lee Brekke, Eleena Koep, Amy Anderson, Richard H. Stanford, Riju Ray

Publikováno v: Chest. 154:767A-768A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f6958f164a77384bab08989c23a4d48f
https://doi.org/10.1016/j.chest.2018.08.692